| Group | Value | 95% CI |
|---|---|---|
| CATCH Group | 10 | |
| Control Group | 5 |
Last reviewed · How we verify
NCT03457103: CATCH
Capnometry-Assisted Breathing Training for COPD
Phase 2 trial testing Capnometry-Assisted Training for COPD to Slow the Breath (CATCH) in Chronic Obstructive Pulmonary Disease in 31 participants. Completed in 2 August 2019.
2 August 2019
Quick facts
| Lead sponsor | NYU Langone Health |
|---|---|
| Phase | Phase 2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 31 |
| Start date | 16 June 2015 |
| Primary completion | 2 August 2019 |
| Estimated completion | 2 August 2019 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Capnometry-Assisted Training for COPD to Slow the Breath (CATCH)
- Pulmonary Rehabilitation (PR)
Conditions studied
- Chronic Obstructive Pulmonary Disease — all drugs for Chronic Obstructive Pulmonary Disease →
Sponsor
NYU Langone Health — full company profile →
Who can join
40 and older, any sex, with Chronic Obstructive Pulmonary Disease. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
The six-minute walk test (6MWT) measures the distance an individual is able to walk over a total of six minutes on a hard, flat surface. The goal is for the individual to walk as far as possible in six minutes.
| Group | Value | 95% CI |
|---|---|---|
| CATCH Group | 39.37 | 14.13 – 64.61 |
| Control Group | 24.99 | -32.53 – 82.52 |
The DMQ-CAT Dyspnea Anxiety is a 14 item scale; each item is scored off a 7 point likert scale for a total range of 0 to 98 where higher scores correlate with higher anxiety
| Group | Value | 95% CI |
|---|---|---|
| CATCH Group | 2.43 | .09 – 4.77 |
| Control Group | -3.16 | -8.89 – 2.57 |
| Group | Value | 95% CI |
|---|---|---|
| CATCH Group | 6.2 | -1.32 – 13.72 |
| Control Group | 3 | -35.12 – 41.12 |
Patient-Reported Outcomes Measurement Information System (PROMIS) Fatigue 7a questionnaire. Raw scores range from 7-35, with higher scores indicating higher levels of fatigue.
| Group | Value | 95% CI |
|---|---|---|
| CATCH Group | -4.18 | -8.16 – -0.21 |
| Control Group | 5.2 | -21.39 – 31.79 |
| Group | Value | 95% CI |
|---|---|---|
| CATCH Group | -2.75 | -7.56 – 2.05 |
| Control Group | -4.2 | -26.26 – 17.87 |
Disease-specific instrument designed to measure impact on overall health, daily life, and perceived well-being in patients with obstructive airways disease. Scores range from 0 to 100, with higher scores indicating more limitations.
| Group | Value | 95% CI |
|---|---|---|
| CATCH Group | -11.76 | -19.68 – -3.83 |
| Control Group | -9.96 | -38.07 – 18.14 |
Sponsor's own description
Capnometry-Assisted Breathing Training for COPD (CATCH) is a behavioral intervention that aims to promote optimal, self-regulated, mindful breathing. A portable capnometer is used in-session to provide continuous visual feedback of Respiratory Rate (RR), End-Tidal Carbon Dioxide Tension (ETCO2), and breathing pattern. The tailored CATCH intervention will emphasize a slow, quiet, regular, nasal breathing pattern, as well as pursed lips breathing (PLB). CATCH is once weekly for 6 weeks, for a total of 6 sessions; each session is approximately 60 minutes long. The principal investigator will implement the CATCH intervention. The principal investigator will implement the CATCH intervention. Patients will use the Address Stress app on a smart phone or computer tablet as part of their home breathing exercises.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Mind-Body Intervention for Dysfunctional Breathing in Chronic Obstructive Pulmonary Disease: Feasibility Study and Lessons Learned.
Norweg AM, Wu Y, Troxel A, Whiteson JH, et al · · 2023 · cited 6× · PMID 36800224 · DOI 10.1089/jicm.2022.0552 -
Acceptability of capnography-assisted respiratory therapy: a new mind-body intervention for COPD.
Norweg AM, Skamai A, Kwon SC, Whiteson J, et al · · 2021 · cited 5× · PMID 34938800 · DOI 10.1183/23120541.00256-2021
Verify or expand the search:
- PubMed search for NCT03457103
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Chronic Obstructive Pulmonary Disease
Currently open trials in the same condition.
- NCT06749262 — Inclined Versus Standard Exercise for COPD Patients · NA · recruiting
- NCT07406659 — Different Inspiratory Muscle Trainings in Patients With COPD · NA · recruiting
- NCT07051707 — Evaluating the Safety and Efficacy of dNerva Lung Denervation System in Patients With COPD · NA · recruiting
- NCT07418736 — A Phase II Study of CM326 in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease · Phase 2 · recruiting
- NCT07069829 — Study of Clinical and Patient-reported Outcomes in Adults With Moderate to Severe COPD Treated With Breztri/Trixeo · recruiting
Other NYU Langone Health trials
Trials by the same sponsor.
- NCT07214519 — Permanent Supportive Housing Overdose Prevention-2 Study · NA · not yet recruiting
- NCT05558267 — Potassium Containing Salt-Substitute in Hemodialysis-Dependent End Stage Kidney Disease · NA · not yet recruiting
- NCT06637852 — Sexual and Urinary Function Improvement for Cancer Survivors · NA · not yet recruiting
- NCT06236087 — Overdose Prevention Centers and Behavioral Health · not yet recruiting
- NCT06462027 — Packed Red Blood Cell Transfusion During Cardiac Arrest · Phase 1 · suspended
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03457103 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by NYU Langone Health
- Last refreshed: 18 August 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03457103.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing